These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

262 related items for PubMed ID: 22465052

  • 1. A novel obatoclax derivative, SC-2001, induces apoptosis in hepatocellular carcinoma cells through SHP-1-dependent STAT3 inactivation.
    Chen KF, Su JC, Liu CY, Huang JW, Chen KC, Chen WL, Tai WT, Shiau CW.
    Cancer Lett; 2012 Aug 01; 321(1):27-35. PubMed ID: 22465052
    [Abstract] [Full Text] [Related]

  • 2. Dovitinib sensitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5 antibody, through SHP-1-dependent inhibition of STAT3.
    Chen KF, Chen HL, Liu CY, Tai WT, Ichikawa K, Chen PJ, Cheng AL.
    Biochem Pharmacol; 2012 Mar 15; 83(6):769-77. PubMed ID: 22230479
    [Abstract] [Full Text] [Related]

  • 3. Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3.
    Tai WT, Cheng AL, Shiau CW, Liu CY, Ko CH, Lin MW, Chen PJ, Chen KF.
    Mol Cancer Ther; 2012 Feb 15; 11(2):452-63. PubMed ID: 22180308
    [Abstract] [Full Text] [Related]

  • 4. Obatoclax analog SC-2001 inhibits STAT3 phosphorylation through enhancing SHP-1 expression and induces apoptosis in human breast cancer cells.
    Liu CY, Su JC, Ni MH, Tseng LM, Chu PY, Wang DS, Tai WT, Kao YP, Hung MH, Shiau CW, Chen KF.
    Breast Cancer Res Treat; 2014 Jul 15; 146(1):71-84. PubMed ID: 24903225
    [Abstract] [Full Text] [Related]

  • 5. A sorafenib derivative and novel SHP-1 agonist, SC-59, acts synergistically with radiotherapy in hepatocellular carcinoma cells through inhibition of STAT3.
    Huang CY, Tai WT, Hsieh CY, Hsu WM, Lai YJ, Chen LJ, Shiau CW, Chen KF.
    Cancer Lett; 2014 Jul 28; 349(2):136-43. PubMed ID: 24735751
    [Abstract] [Full Text] [Related]

  • 6. RFX1-dependent activation of SHP-1 induces autophagy by a novel obatoclax derivative in hepatocellular carcinoma cells.
    Su JC, Tseng PH, Hsu CY, Tai WT, Huang JW, Ko CH, Lin MW, Liu CY, Chen KF, Shiau CW.
    Oncotarget; 2014 Jul 15; 5(13):4909-19. PubMed ID: 24952874
    [Abstract] [Full Text] [Related]

  • 7. Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma.
    Tai WT, Cheng AL, Shiau CW, Huang HP, Huang JW, Chen PJ, Chen KF.
    J Hepatol; 2011 Nov 15; 55(5):1041-8. PubMed ID: 21354226
    [Abstract] [Full Text] [Related]

  • 8. Sorafenib and its derivative SC-49 sensitize hepatocellular carcinoma cells to CS-1008, a humanized anti-TNFRSF10B (DR5) antibody.
    Chen KF, Chen HL, Shiau CW, Liu CY, Chu PY, Tai WT, Ichikawa K, Chen PJ, Cheng AL.
    Br J Pharmacol; 2013 Feb 15; 168(3):658-72. PubMed ID: 22978563
    [Abstract] [Full Text] [Related]

  • 9. Mcl-1-dependent activation of Beclin 1 mediates autophagic cell death induced by sorafenib and SC-59 in hepatocellular carcinoma cells.
    Tai WT, Shiau CW, Chen HL, Liu CY, Lin CS, Cheng AL, Chen PJ, Chen KF.
    Cell Death Dis; 2013 Feb 07; 4(2):e485. PubMed ID: 23392173
    [Abstract] [Full Text] [Related]

  • 10. Honokiol inhibits signal transducer and activator of transcription-3 signaling, proliferation, and survival of hepatocellular carcinoma cells via the protein tyrosine phosphatase SHP-1.
    Rajendran P, Li F, Shanmugam MK, Vali S, Abbasi T, Kapoor S, Ahn KS, Kumar AP, Sethi G.
    J Cell Physiol; 2012 May 07; 227(5):2184-95. PubMed ID: 21792937
    [Abstract] [Full Text] [Related]

  • 11. STAT3 mediates regorafenib-induced apoptosis in hepatocellular carcinoma.
    Tai WT, Chu PY, Shiau CW, Chen YL, Li YS, Hung MH, Chen LJ, Chen PL, Su JC, Lin PY, Yu HC, Chen KF.
    Clin Cancer Res; 2014 Nov 15; 20(22):5768-76. PubMed ID: 25248379
    [Abstract] [Full Text] [Related]

  • 12. RFX-1-dependent activation of SHP-1 inhibits STAT3 signaling in hepatocellular carcinoma cells.
    Su JC, Chiang HC, Tseng PH, Tai WT, Hsu CY, Li YS, Huang JW, Ko CH, Lin MW, Chu PY, Liu CY, Chen KF, Shiau CW.
    Carcinogenesis; 2014 Dec 15; 35(12):2807-14. PubMed ID: 25322871
    [Abstract] [Full Text] [Related]

  • 13. Nintedanib (BIBF-1120) inhibits hepatocellular carcinoma growth independent of angiokinase activity.
    Tai WT, Shiau CW, Li YS, Chang CW, Huang JW, Hsueh TT, Yu HC, Chen KF.
    J Hepatol; 2014 Jul 15; 61(1):89-97. PubMed ID: 24657398
    [Abstract] [Full Text] [Related]

  • 14. Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation.
    Chen KF, Yu HC, Liu TH, Lee SS, Chen PJ, Cheng AL.
    J Hepatol; 2010 Jan 15; 52(1):88-95. PubMed ID: 19913321
    [Abstract] [Full Text] [Related]

  • 15. SC-1, a sorafenib derivative, shows anti-tumor effects in osteogenic sarcoma cells.
    Wang CT, Lin CS, Shiau CW, Chu PY, Hsiao CC, Chiang YL, Tai WT, Chen KF.
    J Orthop Res; 2013 Feb 15; 31(2):335-42. PubMed ID: 22926753
    [Abstract] [Full Text] [Related]

  • 16. Abrogation of constitutive STAT3 activity sensitizes human hepatoma cells to TRAIL-mediated apoptosis.
    Kusaba M, Nakao K, Goto T, Nishimura D, Kawashimo H, Shibata H, Motoyoshi Y, Taura N, Ichikawa T, Hamasaki K, Eguchi K.
    J Hepatol; 2007 Oct 15; 47(4):546-55. PubMed ID: 17602782
    [Abstract] [Full Text] [Related]

  • 17. SC-2001 overcomes STAT3-mediated sorafenib resistance through RFX-1/SHP-1 activation in hepatocellular carcinoma.
    Su JC, Tseng PH, Wu SH, Hsu CY, Tai WT, Li YS, Chen IT, Liu CY, Chen KF, Shiau CW.
    Neoplasia; 2014 Jul 15; 16(7):595-605. PubMed ID: 25047655
    [Abstract] [Full Text] [Related]

  • 18. Signal transducer and activator of transcription 3 as molecular therapy for non-small-cell lung cancer.
    Wang CY, Chao TT, Tai WT, Chang FY, Su WP, Chen YL, Chen PT, Weng CY, Yuan A, Shiau CW, Yu CJ, Chen KF.
    J Thorac Oncol; 2014 Apr 15; 9(4):488-96. PubMed ID: 24736071
    [Abstract] [Full Text] [Related]

  • 19. Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells.
    Chen KF, Yeh PY, Yeh KH, Lu YS, Huang SY, Cheng AL.
    Cancer Res; 2008 Aug 15; 68(16):6698-707. PubMed ID: 18701494
    [Abstract] [Full Text] [Related]

  • 20. Luteolin promotes degradation in signal transducer and activator of transcription 3 in human hepatoma cells: an implication for the antitumor potential of flavonoids.
    Selvendiran K, Koga H, Ueno T, Yoshida T, Maeyama M, Torimura T, Yano H, Kojiro M, Sata M.
    Cancer Res; 2006 May 01; 66(9):4826-34. PubMed ID: 16651438
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.